ArticleHypertension (Dallas, Tex. : 1979)2026
Obstetric History Versus Biomarkers: Hypertension Risk Up to 15 Years Postpartum.
Article in Hypertension (Dallas, Tex. : 1979), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundsFlt-1 (serum soluble fms-like tyrosine kinase-1) to PlGF (placental growth factor) can be used to predict the development of severe preeclampsia. The association between sFlt-1/PlGF during pregnancy and long-term risk of hypertension is unclear.
methodsThis is a retrospective cohort study of patients enrolled from 2006 to 2008 in the ongoing LIFECODES biobank. Mean sFlt-1 and PlGF levels were collected in the second half of pregnancy. Electronic medical record review identified those who developed hypertension over 15 year follow-up. Adjusted Cox proportional hazard models were used to estimate hazard ratios and 95% CI for the time to diagnosis of hypertension.
resultsOf the n=993 participants, n=260 (29.18%) were diagnosed with stage 1 and n=169 (17.0%) were diagnosed with stage 2 hypertension. One hundred thirteen of the participants in the database had a diagnosis of gestational hypertension or preeclampsia. A history of preeclampsia or a history of gestational hypertension was both significantly associated with developing hypertension later in life, with adjusted hazard ratios of 2.17 (95% CI, 1.44-3.28) and 3.50 (95% CI, 2.21-5.54), respectively. We observed no significant association between the hazard of developing hypertension and sFlt-1/PlGF. However, mean PlGF levels in those who remained normotensive in the follow-up were significantly higher, 546.7 pg/mL (SD=369.5), compared with those who developed hypertension, 513.7 pg/mL (SD=389.9;
conclusionsA history of hypertensive disease of pregnancy was significantly associated with the hazard of developing HTN later in life, while elevated sFlt-1/PlGF levels were not. PlGF levels alone were significantly lower in those who developed hypertension later.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.